[{"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$3,150.0 million","upfrontCash":"$750.0 million","newsHeadline":"Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and Seagen Submit BLA for Tisotumab Vedotin to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody\u00ae-CD3xCD20) From Phase 1\/2 Trial in Patients with Relapsed\/Refractory Large B-cell Lymphoma (LBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK\u00ae) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody\u00ae-CD3xCD20) in Relapsed\/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody-CD3xCD20) for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA (pembrolizumab) as First-Line Treatment in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"IO Biotech"},{"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"IO Biotech"},{"company":"Oncology Venture","sponsor":"Sass & Larsen ApS","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture Acquires Full Control of Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Oncology Venture"},{"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP\u00ae Biomarker Patents","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics To Present a Dovitinib-DRP\u00ae e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"company":"Allarity Therapeutics","sponsor":"Oncoheroes Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Presents Dovitinib Survival Data from DRP\u00ae Screened RCC Patients at ESMO 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"company":"Allarity Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"},{"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Allarity Therapeutics"}]
Details:
DuoBody (epcoritamab) is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types.
Lead Product(s):
Epcoritamab
Therapeutic Area: Oncology
Product Name: DuoBody
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
AbbVie Inc
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 18, 2022
Details:
DuoBody (Epcoritamab) demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapy.
Lead Product(s):
Epcoritamab
Therapeutic Area: Oncology
Product Name: DuoBody
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 11, 2022
Details:
Interim results of tisotumab vedotin (Tivdak) plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC).
Lead Product(s):
Tisotumab Vedotin,Pembrolizumab
Therapeutic Area: Oncology
Product Name: Tivdak
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Seagen
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 06, 2022
Details:
Tisotumab vedotin-tftv (TIVDAK®) is an antibody-drug conjugate (ADC) composed of Genmab’s human monoclonal antibody directed to tissue factor and Seagen’s ADC technology that utilizes protease-cleavable linker that covalently attaches MMAE to antibody.
Lead Product(s):
Tisotumab Vedotin,Pembrolizumab
Therapeutic Area: Oncology
Product Name: Tivdak
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Seagen
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 26, 2022
Details:
IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.
Lead Product(s):
IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology
Product Name: IO102
Highest Development Status: Phase III
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 26, 2022
Details:
IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.
Lead Product(s):
IO102,IO103,Pembrolizumab
Therapeutic Area: Oncology
Product Name: IO102
Highest Development Status: Phase III
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 18, 2022
Details:
Multiple DuoBody®-CD3xCD20 ( epcoritamab) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options.
Lead Product(s):
Epcoritamab
Therapeutic Area: Oncology
Product Name: DuoBody
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 12, 2022
Details:
Topline results from first cohort of EPCORE™ NHL-1 phase 1/2, clinical trial evaluating DuoBody-CD3xCD20 (epcoritamab), an investigational subcutaneous bispecific antibody, demonstrated an overall response rate of 63.1 percent as confirmed by IRC.
Lead Product(s):
Epcoritamab
Therapeutic Area: Oncology
Product Name: DuoBody
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
AbbVie Inc
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 13, 2022
Details:
Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s NDA and related PMA.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: TKI258
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 15, 2022
Details:
NDA is supported by Allarity’s previously-filed pre-market approval submission to the FDA for the Dovitinib-DRP® companion diagnostic to select RCC patients most likely to respond to the drug.
Lead Product(s):
Dovitinib
Therapeutic Area: Oncology
Product Name: Dovitinib-DRP
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 22, 2021
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
